Loxapine
From Anvita Health Wiki
Contents |
Introduction
- Tradename: Loxitane.
Indications
- symptomatic management of psychotic disorders
- may be preferred for paranoid patients
Contraindications
- narrow-angle glaucoma
- bone marrow depression
- severe liver disease
- severe cardiac disease
- severe CNS depression or coma
Dosage
- Tabs: 5, 10, 25, 50 mg.
- Liquid: 25 mg/mL.
Pharmacokinetics
- metabolized by liver to many active metabolites
- metabolites excreted in the urine & feces
- elimination 1/2life is 4-5 hours
- elimination via liver
- elimination via kidney
Adverse-effects
- common (> 10%)
- drowsiness
- extrapyramidal symptoms are moderate
- tardive dyskinesia (persistent)
- pseudoparkinsonism
- dystonias
- akathisia
- low anticholinergic & orthostatic hypotensive effects
- less common (1-10%)
- constipation, skin rash, breast enlargement, nausea/vomiting
- uncommon (< 1%)
- tachycardia, arrhythmias, abnormal T-waves with prolonged ventricular repolarization, sedation, restlessness, anxiety, altered central temperature regulation, hyperpigmentation, pruritis, rash, amenorrhea, galactorrhea, gynecomastia, weight gain, adynamic ileus, agranulocytosis*, leukopenia#, retinal pigmentation, urinary retention, overflow incontinence, sexual dysfunction, photosensitivity,
- other
- moderate sedation profile
- neuroleptic malignant syndrome is rare
- QT prolongation
- direct myocardial depression
- seizures (rare)
- increased mortality in elderly
- * Most frequent in women in 4th-10th week of therapy
- # Usually after large doses for prolonged periods
Drug-interactions
Mechanism-of-action
- intermediate/high potency antipsychotic
- has antidepressant properties
- see chorpromazine
More General Terms
Additional Terms
Internet Database
PubChem: 3964
PubChem: 71399
PubChem: 71400
References
- The Pharmacological Basis of Therapeutics, 9th ed. Gilman et al, eds. Permagon Press/McGraw Hill, 1996
- Drug Information & Medication Formulary, Veterans Affairs, Central California Health Care System, 1st ed., Ravnan et al eds, 1998
- Kaiser Permanente Northern California Regional Drug Formulary, 1998
- Schneeweiss S et al, Risk of death with use of conventional versus atypical antipsychotic drugs among elderly patients. CMAJ 2007, 176:627 PMID: [1]
